TY  - CHAP
M1  - Book, Section
TI  - Drug Development, Adverse Drug Events, and Postmarketing Surveillance
A1  - Cantilena, Louis R.
A2  - Nelson, Lewis S.
A2  - Howland, Mary Ann
A2  - Lewin, Neal A.
A2  - Smith, Silas W.
A2  - Goldfrank, Lewis R.
A2  - Hoffman, Robert S.
PY  - 2019
T2  - Goldfrank's Toxicologic Emergencies, 11e
AB  - This  chapter  will  focus  on  drug-induced  diseases  that  occur  as  expected  or  unexpected  adverse  drug  events  (ADEs),  as  a  drug–drug  interaction  or  an  ADE  causing  an  untoward  drug–disease  interaction.  Also  included  in  this  chapter  is  a  brief  overview  of  the  drug  development  process  in  the  United  States  and  specific  aspects  of  the  process  that  relate  to  the  development  of  antidotes.  In  addition,  a  discussion  of  an  approach  to  the  diagnosis  of  drug-induced  disease,  monitoring  of  drug  safety  postapproval,  and  the  suggested  role  for  the  clinical  and  medical  toxicologists  in  the  discovery,  reporting,  and  prevention  of  ADEs.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1163021830
ER  -